Josep Maria D. B. D.
- Country
- Spain
- Department
- Pediatric Orthopedics
Research Overview
- Phase 2 Open-Label Extension Study of Infigratinib in Children with Hypochondroplasia: Safety, Tolerability, and Height Outcomes
- Evaluation of SAR442501 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Pediatric Achondroplasia: A Phase 2, Open-Label, Dose Escalation Study
- Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial Evaluating Infigratinib Efficacy and Safety in Pediatric Achondroplasia Patients
Data & Insights
Has run more than one trial at 4 of 14 partner sites.
Specializations
Growth Disorders Research
This investigator specializes in studying skeletal growth disorders, with particular emphasis on achondroplasia and hypochondroplasia in pediatric populations.
- Pediatric Growth Development
- Skeletal Dysplasia Management
- Growth Velocity Assessment
The research focuses on evaluating novel therapeutic approaches for skeletal growth disorders in children and adolescents.
Therapeutic Innovation
The investigator explores various therapeutic modalities including subcutaneous treatments and oral medications for skeletal growth disorders.
- Novel Drug Development
- Long-term Treatment Protocols
- Administration Methods
Their work encompasses the evaluation of multiple therapeutic compounds targeting growth regulation pathways.
Clinical Assessment
Expertise in conducting comprehensive evaluations of treatment safety and efficacy parameters in pediatric skeletal disorders.
- Safety Monitoring
- Growth Parameters Assessment
- Treatment Tolerability
The research includes systematic monitoring of growth outcomes and treatment responses in pediatric participants.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.